Core Viewpoint - Revvity reported a revenue of $720 million for Q2 2025, reflecting a 4% year-over-year growth, with life sciences and diagnostics contributing $366 million and $354 million respectively [1][2]. Financial Performance - The revenue for Q2 2025 was $720 million, compared to $692 million in the same period last year, marking a 4% increase [2]. - The GAAP operating income from continuing operations was $91 million, up from $86 million year-over-year, with an operating margin of 12.6% compared to 12.4% in the previous year [2][5]. - Life sciences revenue grew by 5% to $366 million from $349 million, while diagnostics revenue increased by 3% to $354 million from $343 million [2][6]. Future Outlook - Revvity raised its full-year revenue guidance for 2025 to between $2.84 billion and $2.88 billion, anticipating an organic growth rate of 2% to 4% [1][6]. - The adjusted earnings per share forecast was also increased to between $4.85 and $4.95 [6].

Core Viewpoint - Levi Strauss has raised its revenue guidance, indicating resilience against the impact of tariffs, leading to a 9% increase in stock price during after-hours trading [1] Revenue Guidance - The company now expects revenue growth of 1% to 2% for the current fiscal year, which is above analysts' average expectations and an improvement from the previous forecast of a decline of 1% to 2% [1] Product Expansion - The positive revenue outlook suggests that the company's efforts to expand into new products and categories are yielding results [1]